Oncolytics Biotech Secures Manufacturing Patent for Pelareorep Through 2044
ONCY•Oncolytics Biotech received a USPTO patent covering proprietary manufacturing methods for pelareorep, securing commercial-scale production protection until 2044. A pending method-of-use patent application is expected to extend protection to 2046, and additional filings planned in 2026 aim to broaden pelareorep’s intellectual property estate.
1. Patent Issuance
Oncolytics Biotech secured a United States patent covering proprietary methods to manufacture pelareorep at commercial scale, with protection lasting until 2044. This patent safeguards key process steps and supports consistent production capacity required for future registration and market supply.
2. Pending Method-of-Use Patent
A method-of-use patent application directed at pelareorep’s immunotherapeutic use remains under USPTO review and, if granted, will extend IP protection into 2046. This application underscores the company’s focus on securing indications and treatment protocols for oncology settings.
3. Planned IP Expansion
Oncolytics plans multiple additional patent filings in 2026 to broaden pelareorep’s intellectual property estate, including formulation, combination therapies and new treatment settings. These filings aim to strengthen exclusivity across gastrointestinal and other oncology indications, enhancing long-term value.
